Thromboembolic Complications in Mild Covid-19 Cases

The aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in COVID-19 cases that did not require hospitalization. For this purpose, patients registered at two different family health centers in Istanbul were retrospectively screened, and their status regarding post-COVID-19 thromboembolic events was recorded. The sociodemographic characteristics, medical history, COVID-19 treatments received, comorbidities, and current medications of all patients were examined and compared with the occurrence of complications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID 19 COVID-19 Cardiovascular Diseases Coronaviridae Infections Coronavirus Infections Embolism Embolism and Thrombosis Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral Post Covid-19 Pulmonary Embolism RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Thromboembolic and Bleeding Complications Thromboembolism Thromboembolism, Venous Thrombosis Vascular Diseases Venous Thromboembolism Venous Thrombosis Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Marmara University Medical School

Istanbul, Turkey (Türkiye)

About this study

Studies on COVID-19 complications in the literature have predominantly focused on patients treated in hospitals, particularly in intensive care units. Data on patients with mild to moderate symptoms who were followed up on an outpatient basis in primary care are quite limited. Therefore, our research investigated the incidence of thrombotic events within six months following infection in mild to moderate COVID-19 cases and the factors that might influence these events. Records of 961 individuals registered at two different family health centers in Istanbul were reviewed. Patients were contacted by phone, informed about the study, and data regarding their sociodemographic characteristics, medical histories, COVID-19 infection experiences, and medications used were collected. Comparative analyses (Fisher's exact test) and logistic regression tests were conducted.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Being over 18 years of age
Having had a confirmed COVID-19 infection verified by a PCR test
Being monitored at a family health center without requiring hospitalization during the COVID-19 course
Having at least 6 months elapsed since the infection
Availability of the patient's medical records
Absence of any language barrier or health issue that would prevent communication with the patient

Exclusion criteria

Being under 18 years of age
Having had less than 6 months since the COVID-19 infection
Presence of any condition that prevents communication with the patient
Incomplete or missing medical records of the patient
History of hospitalization due to COVID-19 infection

Treatment and study plan

Primary outcomes

The frequency of thromboembolic complications in COVID-19 patients not requiring hospitalization.

Time frame: january-june 2022

Patients registered at a family health center were retrospectively reviewed, and those with a history of COVID-19 PCR positivity who had been followed up as outpatients were included. The occurrence of venous or arterial thromboembolism within the first 6 months after infection was recorded from their medical reports, and the frequency was calculated.
The relationship between patients' comorbidities and the occurrence of thromboembolic events post-COVID.

Time frame: january-june 2022

The patients' existing chronic conditions from the time of their COVID-19 infection were recorded by reviewing the family medicine system. The presence of chronic diseases was then analyzed in comparison to the occurrence of thrombosis within the first 6 months following COVID-19 infection.
The relationship between patients' medications and the occurrence of thromboembolic events post-COVID.

Time frame: january-june 2022

The medications regularly used by patients for their chronic conditions since the time of their COVID-19 infection were noted by reviewing records in the family medicine system. These medications were then analyzed in comparison to the occurrence of thrombosis within the first 6 months following COVID-19 infection.

Sponsors and collaborators

Lead sponsor

Marmara University Pendik Training and Research Hospital

Other

Registry information

Official study title

Thromboembolic Complications Post-COVID-19: What is the Risk in Mild-Moderate Cases?

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Nov 19, 2024
Registry last updated: Nov 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed